Literature DB >> 2594392

Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature.

Michael C Rowbotham1, Howard L Fields.   

Abstract

Twelve otherwise healthy patients with longstanding postherpetic neuralgia (PHN) were prospectively studied using clinical examination, infrared thermography and response to local anesthetic skin infiltration. All had at least 2 of 3 possible components to their PHN pain: continuous, neuralgic, or allodynic. In patients with allodynia, maximal reported pain and the location of maximal allodynia on sensory examination were largely overlapping and were often warm thermographically. Areas of dense sensory loss and skin scarring without allodynia were usually cool thermographically. Local anesthetic skin infiltration produced substantial pain relief in all 9 patients (essentially complete relief in 7) with allodynia: the 3 patients with predominantly continuous pain were not relieved. In 7 of 8 skin infiltration responders, the same dose of lidocaine i.m. in the deltoid muscle also produced significant, though less complete pain relief. These results suggest that PHN patients can be divided into at least 2 clinical groups: those with predominantly continuous pain localized to a region of significant sensory loss and those in whom allodynia is the most prominent sensory disturbance. The latter group has pain localized to areas with relatively preserved sensation. The differences in clinical features and response to lidocaine suggest that there are at least 2 different mechanisms contributing to the pain of PHN.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2594392     DOI: 10.1016/0304-3959(89)90001-8

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  15 in total

1.  [Not Available].

Authors:  E G Boss; W Förster; F T Schuh
Journal:  Schmerz       Date:  1991-03       Impact factor: 1.107

2.  Lidocaine patch 5%.

Authors:  A M Comer; H M Lamb
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia.

Authors:  Pamela S Davies; Bradley S Galer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

5.  Painful peripheral neuropathies.

Authors:  P Marchettini; M Lacerenza; E Mauri; C Marangoni
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

6.  [Pain therapy in herpes zoster and post-zoster neuralgia.].

Authors:  T Zenz; M Zenz; M Tryba
Journal:  Schmerz       Date:  1994-03       Impact factor: 1.107

Review 7.  The Potential Role of Sensory Testing, Skin Biopsy, and Functional Brain Imaging as Biomarkers in Chronic Pain Clinical Trials: IMMPACT Considerations.

Authors:  Shannon M Smith; Robert H Dworkin; Dennis C Turk; Ralf Baron; Michael Polydefkis; Irene Tracey; David Borsook; Robert R Edwards; Richard E Harris; Tor D Wager; Lars Arendt-Nielsen; Laurie B Burke; Daniel B Carr; Amy Chappell; John T Farrar; Roy Freeman; Ian Gilron; Veeraindar Goli; Juergen Haeussler; Troels Jensen; Nathaniel P Katz; Jeffrey Kent; Ernest A Kopecky; David A Lee; William Maixner; John D Markman; Justin C McArthur; Michael P McDermott; Lav Parvathenani; Srinivasa N Raja; Bob A Rappaport; Andrew S C Rice; Michael C Rowbotham; Jeffrey K Tobias; Ajay D Wasan; James Witter
Journal:  J Pain       Date:  2017-02-27       Impact factor: 5.820

Review 8.  Herpes zoster infection and postherpetic neuralgia.

Authors:  R B Tenser
Journal:  Curr Neurol Neurosci Rep       Date:  2001-11       Impact factor: 6.030

Review 9.  Postherpetic neuralgia in the cancer patient.

Authors:  E Lojeski; R A Stevens
Journal:  Curr Rev Pain       Date:  2000

10.  Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin.

Authors:  Gunnar Wasner; Anne Kleinert; Andreas Binder; Jörn Schattschneider; Ralf Baron
Journal:  J Neurol       Date:  2005-03-23       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.